| RS2509274346 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Breast-ovarian cancer |
| RS2509274419 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Breast-ovarian cancer |
| RS2509274602 |
POLG
|
Health Risk |
Pathogenic |
Progressive sclerosing poliodystrophy, Progressive sclerosing poliodystrophy |
| RS2509274733 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2509274839 |
POLG
|
Health Risk |
Pathogenic/Likely pathogenic |
Progressive sclerosing poliodystrophy, Progressive external ophthalmoplegia with mitochondrial DNA deletions |
| RS2509275021 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509275138 |
POLG
|
Health Risk |
Likely pathogenic |
Progressive sclerosing poliodystrophy, Progressive sclerosing poliodystrophy |
| RS2509275155 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Breast-ovarian cancer |
| RS2509275252 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509275463 |
MED13
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder 61, Intellectual developmental disorder 61 |
| RS2509275684 |
POLG
|
Health Risk |
Likely pathogenic |
Progressive sclerosing poliodystrophy, Progressive sclerosing poliodystrophy |
| RS2509275801 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Fanconi anemia complementation group O |
| RS2509275911 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509275974 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Fanconi anemia complementation group O |
| RS2509276003 |
RAD51C
|
Health Risk |
Likely pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2509276286 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509276392 |
POLG
|
Health Risk |
Pathogenic |
Progressive sclerosing poliodystrophy, Progressive sclerosing poliodystrophy |
| RS2509276440 |
RAD51C
|
Health Risk |
Pathogenic/Likely pathogenic |
Breast-ovarian cancer, familial |
| RS2509276500 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509276573 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Hereditary cancer-predisposing syndrome |
| RS2509277006 |
POLG
|
Health Risk |
Pathogenic |
Progressive sclerosing poliodystrophy, Progressive sclerosing poliodystrophy |
| RS2509277010 |
MED13
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Inborn genetic diseases |
| RS2509277154 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509277230 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509277257 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509277315 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509277469 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509277475 |
POLG
|
Health Risk |
Likely pathogenic |
Progressive sclerosing poliodystrophy, Progressive external ophthalmoplegia with mitochondrial DNA deletions |
| RS2509277695 |
POLG
|
Health Risk |
Pathogenic |
Progressive sclerosing poliodystrophy, Progressive sclerosing poliodystrophy |
| RS2509277864 |
NAGS
|
Health Risk |
Pathogenic/Likely pathogenic |
Hyperammonemia, type III |
| RS2509277915 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509277941 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509278357 |
POLG
|
Health Risk |
Likely pathogenic |
— |
| RS2509279402 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509279497 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509279961 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509280209 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509280484 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509280530 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509280602 |
NAGS
|
Health Risk |
Conflicting classifications of pathogenicity |
Hyperammonemia, type III |
| RS2509281199 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509281503 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509281618 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509281642 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509281686 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509281752 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509281880 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2509281902 |
MED13
|
Health Risk |
Pathogenic |
Intellectual developmental disorder 61, Intellectual developmental disorder 61 |
| RS2509282138 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2509282144 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2509282203 |
MED13
|
Health Risk |
Pathogenic/Likely pathogenic |
Intellectual developmental disorder 61, Intellectual developmental disorder 61 |
| RS2509282650 |
MED13
|
Health Risk |
Likely pathogenic |
MED13-related disorder, MED13-related disorder |
| RS2509282682 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Fanconi anemia complementation group O |
| RS2509283109 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2509283244 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2509283306 |
SCN4A
|
Health Risk |
Conflicting classifications of pathogenicity |
Hyperkalemic periodic paralysis, Hyperkalemic periodic paralysis |
| RS2509283402 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509283438 |
NAGS
|
Health Risk |
Pathogenic/Likely pathogenic |
Hyperammonemia, type III |
| RS2509283453 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2509283581 |
RAD51C
|
Health Risk |
Likely pathogenic |
Breast-ovarian cancer, familial |
| RS2509283705 |
RAD51C
|
Health Risk |
Likely pathogenic |
Hereditary cancer-predisposing syndrome, Breast-ovarian cancer |
| RS2509283811 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509283908 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS2509284285 |
SCN4A
|
Health Risk |
Pathogenic |
Congenital myopathy 22B, severe fetal |
| RS2509284731 |
SRSF1
|
Health Risk |
Pathogenic |
Intellectual disability, Neurodevelopmental delay |
| RS2509284743 |
DGKE
|
Health Risk |
Pathogenic |
— |
| RS2509284749 |
SRSF1
|
Health Risk |
Pathogenic |
Intellectual disability, Neurodevelopmental delay |
| RS2509285055 |
SCN4A
|
Health Risk |
Pathogenic |
Hyperkalemic periodic paralysis, Hyperkalemic periodic paralysis |
| RS2509285181 |
SCN4A
|
Health Risk |
Likely pathogenic |
Paramyotonia congenita of Von Eulenburg, Paramyotonia congenita of Von Eulenburg |
| RS2509285182 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509285208 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509285270 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509285298 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS2509285308 |
SCN4A
|
Health Risk |
Pathogenic |
Hyperkalemic periodic paralysis, Hyperkalemic periodic paralysis |
| RS2509285379 |
SCN4A
|
Health Risk |
Likely pathogenic |
Congenital myopathy 22B, severe fetal |
| RS2509285683 |
SRSF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurodevelopmental delay, Intellectual disability |
| RS2509285717 |
SRSF1
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2509286735 |
SCN4A
|
Health Risk |
Conflicting classifications of pathogenicity |
Hyperkalemic periodic paralysis, 7 conditions |
| RS2509287238 |
SRSF1
|
Health Risk |
Pathogenic |
Intellectual disability, Neurodevelopmental delay |
| RS2509287507 |
PNPO
|
Health Risk |
Likely pathogenic |
Pyridoxal phosphate-responsive seizures, Pyridoxal phosphate-responsive seizures |
| RS2509287599 |
SRSF1
|
Health Risk |
Pathogenic |
Intellectual disability, Neurodevelopmental delay |
| RS2509287701 |
SRSF1
|
Health Risk |
Pathogenic |
Intellectual disability, Neurodevelopmental delay |
| RS2509287979 |
SCN4A
|
Health Risk |
Pathogenic |
Hyperkalemic periodic paralysis, Hyperkalemic periodic paralysis |
| RS2509289236 |
SCN4A
|
Health Risk |
Likely pathogenic |
Congenital myopathy 22B, severe fetal |
| RS2509290322 |
SRSF1
|
Health Risk |
Pathogenic |
Intellectual disability, Neurodevelopmental delay |
| RS2509290420 |
SRSF1
|
Health Risk |
Pathogenic |
Intellectual disability, Neurodevelopmental delay |
| RS2509290730 |
SCN4A
|
Health Risk |
Pathogenic |
Congenital myopathy 22A, classic |
| RS2509291006 |
SCN4A
|
Health Risk |
Likely pathogenic |
Potassium-aggravated myotonia, Potassium-aggravated myotonia |
| RS2509291040 |
SCN4A
|
Health Risk |
Likely pathogenic |
Hyperkalemic periodic paralysis, Hyperkalemic periodic paralysis |
| RS2509291965 |
PNPO
|
Health Risk |
Likely pathogenic |
Pyridoxal phosphate-responsive seizures, Pyridoxal phosphate-responsive seizures |
| RS2509293167 |
SCN4A
|
Health Risk |
Pathogenic |
Hyperkalemic periodic paralysis, Hyperkalemic periodic paralysis |
| RS2509293410 |
PNPO
|
Health Risk |
Pathogenic |
Pyridoxal phosphate-responsive seizures, Pyridoxal phosphate-responsive seizures |
| RS2509293643 |
PNPO
|
Health Risk |
Pathogenic |
Pyridoxal phosphate-responsive seizures, Pyridoxal phosphate-responsive seizures |
| RS2509294585 |
PNPO
|
Health Risk |
Pathogenic |
Pyridoxal phosphate-responsive seizures, Pyridoxal phosphate-responsive seizures |
| RS2509299260 |
DGKE
|
Health Risk |
Pathogenic |
— |
| RS2509299416 |
RAD51C
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2509299426 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2509299464 |
CHRNE
|
Health Risk |
Pathogenic/Likely pathogenic |
Congenital myasthenic syndrome 4A, Congenital myasthenic syndrome 4A |
| RS2509299493 |
CHRNE
|
Health Risk |
Pathogenic/Likely pathogenic |
Congenital myasthenic syndrome 4A, Congenital myasthenic syndrome 4B |
| RS2509299617 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, RAD51C-related disorder |